[1]张科乾,吴小姣,余松涛,等.卡培他滨或贝伐单抗用于结直肠癌维持治疗的回顾性分析[J].第三军医大学学报,2018,40(08):717-722.
 ZHANG Keqian,WU Xiaojiao,YU Songtao,et al.Efficacy of maintenance therapy with capecitabine versus bevacizumab for colorectal cancer[J].J Third Mil Med Univ,2018,40(08):717-722.
点击复制

卡培他滨或贝伐单抗用于结直肠癌维持治疗的回顾性分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第08期
页码:
717-722
栏目:
临床医学
出版日期:
2018-04-30

文章信息/Info

Title:
Efficacy of maintenance therapy with capecitabine versus bevacizumab for colorectal cancer
作者:
张科乾吴小姣余松涛王喆彭渝王筱姣谢赣丰阮志华梁后杰
陆军军医大学(第三军医大学)第一附属医院肿瘤科
Author(s):
ZHANG Keqian WU Xiaojiao YU Songtao WANG Zhe PENG Yu WANG Xiaojiao XIE Ganfeng RUAN Zhihua LIANG Houjie

Department of Oncology, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
转移性结直肠癌维持治疗卡培他滨贝伐单抗  
Keywords:
metastatic colorectal cancer maintenance therapy capecitabine bevacizumab
分类号:
R181.32;R730.53;R735.3
文献标志码:
A
摘要:

目的    分析卡培他滨或贝伐单抗用于转移性结直肠癌维持治疗的疗效和安全性。方法    回顾性分析2012年1月至2016年5月在我院病理诊断为“任何原发肿瘤”(primary tumor,T)、“任何区域淋巴结”(regional lymph nodes,N)、“远处转移”(distant metastasis,M)1期(TXNXM1)的结直肠癌接受维持治疗的患者病例资料。予以一线标准方案化疗,待病情缓解或稳定后,按照维持治疗方案的不同分为卡培他滨维持治疗组和贝伐单抗维持治疗组,评价两组患者维持治疗的疗效及不良事件。结果    本研究共纳入病例66例,卡培他滨组41例,贝伐单抗组25例。卡培他滨维持化疗组中位无疾病进展生存时间(progression-free survival,PFS)为 5.6个月,贝伐单抗维持治疗组中位PFS为7.7个月,两组比较无统计学差异(HR:1.171,95%CI:0.701~1.966,P>0.05)。卡培他滨维持治疗组中位总生存时间(overall survival,OS)为 28.2个月,贝伐单抗维持治疗组中位OS为31.9个月,两组比较无统计学差异(HR:1.143,95%CI:0.602~2.180,P>0.05)。两组均无Ⅳ级不良事件发生,卡培他滨维持治疗组手足综合征发生率较高(P<0.05),贝伐单抗维持治疗组出血发生率较高(P<0.05),其他不良反应差异无统计学意义(P>0.05)。结论    贝伐单抗用于转移性结直肠癌维持治疗相较卡培他滨显示出更长的疾病控制时间和总生存时间,但无统计学差异;有出血风险的患者建议选择卡培他滨进行维持化疗。

Abstract:

Objective    To assess the clinical efficacy and safety of capecitabine versus bevacizumab for maintenance therapy in patients with metastatic colorectal cancer. Methods    This retrospective comparative study was conducted among patients with pathologically confirmed metastatic colorectal cancer in stage TXNXM1 treated in Southwest Hospital between January, 2012 and May, 2016. The patients receiving XELOX/FOLFOX ± bevacizumab chemotherapy with subsequent partial response (PR) or stable disease (SD) were identified and divided into two groups according to the maintenance therapy (capecitabine versus bevacizumab) they received until progression or intolerance. The efficacy and adverse events were compared between the two groups. Results    A total of 66 cases were included in the analysis, including 41 in capecitabine group and 25 in bevacizumab group. In capecitabine group, maintenance therapy resulted in a median progression-free survival (PFS) of 5.6 months, as compared to 7.7 months in bevacizumab group (HR=1.171, 95%CI: 0.701-1.966, P=0.211). The median overall survival (OS) of the patients was 28.2 months in capecitabine group and 31.9 months in bevacizumab group, showing no significant difference between the two groups (HR=1.143, 95%CI: 0.602-2.180, P=0.441). No grade 4 adverse events occurred in the two groups, but a higher incidence of extremities syndrome in capecitabine group (P=0.026) and a higher incidence of bleeding in beacizumab group (P=0.043) were recorded; the incidences of other adverse events were similar between the two groups (P>0.05). Conclusion    Compared with capecitabine, bevacizumab for maintenance therapy achieves a longer disease control time and a longer overall survival time in patients with metastatic colorectal cancer, although such differences are not statistical significant. Maintenance chemotherapy with capecitabine is recommended for patients at risk of bleeding.

参考文献/References:


[1]TOURNIGAND C,  CERVANTES A,  FIGER A,  et al. OPTIMOX1:  a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stopandGo fashion in advanced colorectal cancer—a GERCOR study[J]. J Clin Oncol,  2006,  24(3):  394-400. DOI: 10.1200/JCO.2005.03.0106.
[2]CHIBAUDEL B,  MAINDRAULTGOEBEL F,  LLEDO G,  et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study[J]. J Clin Oncol,  2009,  27(34):  5727-5733. DOI: 10.1200/JCO.2009.23.4344.
[3]YALCIN S,  USLU R,  DANE F,  et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer:  phase III 'Stop and Go’ study results--a Turkish Oncology Group Trial[J]. Oncology,  2013,  85(6):  328-335. DOI: 10.1159/000355914.
[4]CUNNINGHAM D,  LANG I,  MARCUELLO E,  et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with  previously untreated metastatic colorectal cancer (AVEX):  an openlabel,  randomised phase 3 trial.[J]. Lancet Oncol. 2013 Oct;14(11): 1077-1085. DOI:  10.1016/S14702045 (13)701542.
[5]CREMOLINI C,  LOUPAKIS F,  ANTONIOTTI C, et al.FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as firstline treatment of patients with metastatic colorectal cancer:  updated overall survival and molecular subgroup analyses of the open-label,  phase 3 TRIBE study.[J]. Lancet Oncol. 2015 Oct;16(13): 1306-1315. DOI:  10.1016/S1470-2045(15)001229.
[6]SIMKENS L H,  VAN TINTEREN H,  MAY A,  et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal  cancer (CAIRO3):  a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J]. Lancet,  2015,  385(9980):  1843-1852. DOI: 10.1016/S0140-6736(14)62004-3.
[7]HEGEWISCHBECKER S, GRAEVEN U, LERCHENMULLER C A, et al. Maintenance strategies after firstline oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207):  a randomised,  noninferiority,  openlabel,  phase 3 trial[J]. Lancet Oncol,  2015,  16(13):  1355-1369. DOI: 10.1016/S1470-2045(15)00042-X.
[8]NAKAYAMA G, ISHIGURE K, YOKOYAMA H, et al.The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer:  a multicenter,  single-arm,  phase II study (CCOG0902) [J]. BMC Cancer. 2017 Apr 4;17(1): 243. DOI:  10.1186/s12885-017-3245-1.
[9]WADDELL T,  GOLLINS S,  SOE W,  et al. Phase II study of shortcourse capecitabine plus oxaliplatin (XELOX) followed by  maintenance capecitabine in advanced colorectal cancer:  XelQuali study[J]. Cancer Chemother Pharmacol,  2011,  67(5):  1111-1117. DOI: 10.1007/s00280-010-1322-0.
[10]杨冬阳, 黎莹, 刘建化, 等. 转移性结直肠癌化疗控制后卡培他滨维持治疗分析[J]. 实用医学杂志,  2013(08):  1299-1302. DOI: 10.3969/j.issn.1006-5725.2013.08.037.
YANG D Y, LI Y, LIU J H, et al.Study of Capecitabine maintenance therapy effectiveness on metastic colorectal cancer patients with disease optimally controlled after the chemotherapy[J]. J Prac Med,  2013(08):  1299-1302. DOI: 10.3969/j.issn.1006-5725.2013.08.037
[11]徐骏, 况晶茹, 胡迎宾. 卡培他滨在转移性结直肠癌维持化疗中的疗效观察[J]. 现代诊断与治疗,  2015(07):  1494-1495.
XU J, KUANG J R, HU Y B. The therapeutic effect of capecitabine in the maintenance of chemotherapy for metastatic colorectal cancer[J]. Mod Diagn Treatm,  2015(07):  1494-1495.
[12]井小会.卡培他滨联合奥沙利铂序贯卡培他滨维持治疗转移性结直肠癌[J]. 医药论坛杂志,  2016(07):  57-59.
JING X H. Capecitabine plus Oxaliplatin as firstline treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer[J]. J Med Forum,  2016(07):  57-59.
[13]MARTINELLI E, SFORZA V, CARDONE C, et al.Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with longterm efficacy of regorafenib treatment[J]. ESMO Open. 2017 Jul 29;2(3): e000177. DOI:  10.1136/esmoopen-2017-000177.
[14]KANAT O, ERTAS H, CANER B. Platinum-induced neurotoxicity:  A review of possible mechanisms. [J]. World J Clin Oncol. 2017 Aug 10;8(4): 329-335. DOI:  10.5306/wjco.v8.i4.329.
[15]ZHAO L, WANG J, LI H, et al. Metaanalysis comparing maintenance strategies with continuous therapy and complete chemotherapyfree interval strategies in the treatment of metastatic colorectal cancer.[J]. Oncotarget, 2016 May 31;7(22): 33418-33428. DOI:  10.18632/oncotarget.8644.
[16]TAMBURINI E,  RUDNAS B,  SANTELMO C,  et al. Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer:  A metaanalysis of randomized clinical trials. [J]. Crit Rev Oncol Hematol. 2016 Aug;104: 115-123. DOI:  10.1016/j.critrevonc.2016.05.016.
[17]马伯敏, 徐爱平, 马妮娜.晚期结直肠癌患者维持治疗的必要性[J].中国医院用药评价与分析, 2014(9): 769-771. DOI: 10.14009/j.issn.1672-2124.2014.09.001
MA B M, XU A P, MA N N. The necessity to maintain treatment for patients with advanced colorectal cancer[J]. Evalua Analy Druguse Hosp China, 2014(9): 769-771.DOI: 10.14009/j.issn.16722124.2014.09.001
[18]刘佳, 李文忠, 夏秀娟, 等.转移性结直肠癌维持治疗的进展[J]. 肿瘤学杂志, 2016, 22(5): 344-348. DOI: 10.11735/j.issn.1671-170X.2016.05.B002.
LIU J, LI W Z, XIA X J, et al. Progress on Maintenance Therapy for Metastatic Colorectal Cancer[J]. J Chin Oncol, 2016, 22(5): 344-348. DOI: 10.11735/j.issn.1671-170X.2016.05.B002.
[19]DIAZRUBIO E, GOMEZESPANA A, MASSUTI B, et al. Firstline XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer:  the phase III MACRO TTD study[J]. Oncologist,  2012,  17(1):  15-25. DOI: 10.1634/theoncologist.2011-0249.
[20]周易, 王兰君, 李萍, 等.替吉奥维持治疗晚期结直肠癌的临床效果[J].中国医药导报, 2016, 13(14): 96-99.
ZHOU Y, WANG L J, LI P,  et al.Clinical efficacy of S1 maintenance therapy of metastatic colorectal cancer. [J].China Med Herald,  2016, 13(14): 96-99.
[21]LI Y H, LUO H Y, WANG F H, et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as firstline treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer[J]. J Cancer Res Clin Oncol,  2010,  136(4):  503-510. DOI: 10.1007/s00432-009-0682-5.

更新日期/Last Update: 2018-04-28